GLAND2024-04-012024-06-30 GLAND2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member GLAND2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member GLAND2024-06-30 GLAND2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543245 GLAND NOTLISTED Gland Pharma Limited Equity 2024-04-01 2025-03-31 2024-08-06 2024-07-19 INR Millions First quarter 15:00:00 16:50:00 2024-08-06 2024-08-06 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Standalone 10120240000.00 484900000.00 10605140000.00 3676870000.00 65750000.00 1042580000.00 1076770000.00 9110000.00 408170000.00 1322740000.00 7601990000.00 3003150000.00 0.00 3003150000.00 762120000.00 11820000.00 773940000.00 0.00 2229210000.00 0.00 0.00 0.00 0.00 2229210000.00 -4650000.00 2224560000.00 2224560000.00 0.00 164750000.00 1 13.53 13.53 0.00 0.00 13.53 13.53 1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2024 ( Unaudited Standalone Financial Results ) of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 6, 2024.The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon. 2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the Listing requirements ). 3. The figures of the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review. 4. The Company is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'. Refer the signed results uploaded for the complete notes. Other expenses 1028580000.00 Power and fuel 294160000.00 Remeasurement of defined benefit plans -6210000.00 -6210000.00 -1560000.00 0.00